Analysts See $-0.01 EPS for ChromaDex Corporation (CDXC)

February 23, 2018 - By Adrian Erickson

 Analysts See $ 0.01 EPS for ChromaDex Corporation (CDXC)

Analysts expect ChromaDex Corporation (NASDAQ:CDXC) to report $-0.01 EPS on March, 15.They anticipate $0.05 EPS change or 83.33 % from last quarter’s $-0.06 EPS. After having $-0.07 EPS previously, ChromaDex Corporation’s analysts see -85.71 % EPS growth. The stock increased 2.73% or $0.14 during the last trading session, reaching $5.26. About 373,091 shares traded. ChromaDex Corporation (NASDAQ:CDXC) has declined 38.10% since February 23, 2017 and is downtrending. It has underperformed by 54.80% the S&P500.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company has market cap of $282.97 million. The firm offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside , a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It currently has negative earnings. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications.

More recent ChromaDex Corporation (NASDAQ:CDXC) news were published by: which released: “ChromaDex Corporation Reports Preliminary 2017 Results” on February 12, 2018. Also published the news titled: “ChromaDex Chairman Stephen Allen Will Retire from Board of Directors” on February 16, 2018.‘s news article titled: “ChromaDex to Present at the 3rd Annual NAD+ Summit” with publication date: January 24, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.